LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 3, 2006--NitroMed, Inc. (NASDAQ: NTMD) today reported financial results for the three- and six-month periods ended June 30, 2006. Total revenue for the three-month period ended June 30, 2006 was $2.9 million compared to $0.4 million for the same period in 2005, an increase of $2.5 million. Total revenue for the six-month period ended June 30, 2006 was $5.2 million compared to $0.8 million for the same period in 2005, an increase of $4.4 million. Product sales of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) accounted for all of the Company’s revenue during the first half of 2006. License fees accounted for all of the Company’s revenue during the first half of 2005. BiDil was commercially launched in July 2005.
